These suggest that our simple immunohistochemical panel comprising Ki67 and p53 is a promising tool for distinguishing between “luminal-subtype-A” and “luminal-subtype-B” breast cancers and management of patients with HR-positive breast cancer. Here, MKI67 is linked to breast carcinoma.